Loading
Nice oncologist who led TPExtreme, the GORTEC trial that showed the shorter TPEx regimen is a reasonable alternative to EXTREME for recurrent or metastatic head and neck cancer.
Joël Guigay is a medical oncologist at Centre Antoine Lacassagne in Nice and a leader of the French GORTEC head and neck group. He was first author of the 2021 Lancet Oncology report of TPExtreme, the phase 2 trial comparing docetaxel, cisplatin and cetuximab (TPEx) with the EXTREME regimen as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma; TPEx did not lengthen survival but was less toxic and shorter, and is used as an alternative.
| Title | Journal | Year |
|---|---|---|
| TPExtreme (GORTEC 2014-01): docetaxel, cisplatin and cetuximab versus the EXTREME regimen in recurrent or metastatic head and neck cancer | The Lancet Oncology | 2021 |
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, trialist.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, trialist.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tags head-and-neck, trialist.
Shares TPExtreme (GORTEC 2014-01), Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, trialist.
Shares Head and neck squamous cell carcinoma and the tag head-and-neck.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma and the tag head-and-neck.